Markets
Business
Investing
Tech
Politics
CNBC TV
Watchlist
Investing Club
PRO

Government Agencies FDA

  • Controversial drug Zohydro here to stay?
    Controversial drug Zohydro here to stay?   

    CNBC's Sheila Dharmarajan discusses the new pain killer Zohydro which contains the same addictive elements as Oxycodone.

  • Controversy grows over potent pain drug Zohydro
    Controversy grows over potent pain drug Zohydro   

    Some medical experts and lawmakers are urging the FDA to reconsider its approval of the new narcotic painkiller Zohyrdo, reports CNBC's Sheila Dharmarajan.

  • Annie's CEO: Lowered guidance on higher commodity price
    Annie's CEO: Lowered guidance on higher commodity price   

    John Foraker, Annie's CEO, discusses why its consumers are interested in non-GMO products. "Lowering our guidance had nothing to do with genetically modified ingredients," he explains.

  • Annie's CEO: Nutrition label change cost will be negligible
    Annie's CEO: Our anti-GMO edge   

    The Food and Drug Administration announced it wants to revamp nutrition labels on foods. John Foraker, Annie's CEO, discusses how a label change might impact his business.

  • Mylan CEO: Affordable medicine for 7 million people
    Mylan CEO: Affordable medicine for 7 billion people   

    Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.

  • Food label makeover
    Food label makeover   

    The White House and the U.S. Food and Drug Administration is proposing to change nutrition facts labeling. Meme Roth, National Action Against Obesity president, and Katherine Mangu-Ward, Reason Magazine managing editor, share their opinions.

  • Danger of energy drinks
    Danger of energy drinks   

    The attorney suing energy drink maker Monster, Kevin Goldberg of Goldberg, Finnegan and Mester, responds to Monster's statement claiming there is no evidence the drinks have caused or contributed to any injury whatsoever.

  • How sweet it is! Nutrition labels getting facelift

    Nutritionists want the FDA to make the number of calories more prominent and the amount of added sugar included.

  • Neurocrine Biosciences CEO on stock spike
    Neurocrine Biosciences CEO on TD treatment   

    Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.

  • Companies ditching genetically modified ingredients
    Companies ditching genetically modified ingredients   

    Discussing whether foods DETAILColin O'Neil, The Center For Food Safety, and Mark Connelly, CLSA analyst.

  • Consumer Reports tests chicken for bacteria
    Consumer Reports tests for sick chicken   

    Consumer Reports says 48 million people get sick from salmonella every year. CNBC's Jane Wells reports Consumer Reports tested more than 300 chicken breasts bought across the U.S., and found bacteria in nearly all of them.

  • FDA joins battle to save US citrus
    FDA joins battle to save US citrus   

    Secretary of Agriculture Tom Vilsack discusses the government's plan to help save millions of acres from citrus greening disease.

  • A tablet of flibanserin at Sprout Pharmaceuticals in Raleigh, N.C.
    Female libido drug in limbo after FDA roadblock

    The search for a pill that boosts sexual desire in women has hit another roadblock, raising questions about future of female libido drugs.

  • Ground beef in a meat department of a supermarket.
    Why the FDA is worried about antibiotics in meat

    The Food and Drug Administration is phasing out the use of antibiotics in meat over concerns about antibiotic-resistant bacteria.

  • Docs push statins, gastric surgery for heart cures

    Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.

  • FDA is banning this to save your life

    The move to ban trans fats could prevent 20,000 heart attacks a year and 7,000 deaths, FDA Commissioner Margaret Hamburg said.

  • Shutdown not huge for biotech: Pro
    Shutdown not huge for biotech: Pro   

    How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.

  • Cramer: PMs could double down on this stock

    Up 54% ytd, if pros must buy health care, Cramer thinks they’ll take a long hard look at this stock.

  • Why Southern cops fear a menthol cigarette ban

    Current and ex-law enforcement officials warn that a menthol cigarette ban could spark a black market boom in the smokes.

  • FDA considering online e-cig sales ban
    FDA considering online e-cig sales ban   

    Microsoft CEO Steve Ballmer is giving a 12-month notice of his retirement, and the FDA is considering a ban on online sales of e-cigarettes. CNBC's John Carney and Simon Hobbs discuss.